Recombinant Tupaia glis Hemoglobin subunit alpha (HBA)

What is Tupaia glis Hemoglobin subunit alpha (HBA) and why is it significant for comparative studies?

Tupaia glis (common tree shrew) hemoglobin subunit alpha (HBA) is the alpha polypeptide chain component of the hemoglobin tetramer in this species. The significance of this protein stems from its evolutionary positioning—tree shrews (Tupaia spp.) represent a mammalian lineage with close phylogenetic relationship to primates, making their hemoglobin an important comparative model for understanding evolutionary adaptations in oxygen transport proteins .

The alpha chain of tupai hemoglobin consists of 141 amino acid residues, with 27 positions differing from those found in human adult hemoglobin . This intermediate evolutionary position makes it valuable for researchers studying the molecular evolution of hemoglobin and the structural basis for functional adaptations in oxygen-binding proteins.

How does the amino acid sequence of Tupaia glis HBA compare to human HBA?

The alpha chain of Tupaia glis hemoglobin shares approximately 80.9% sequence identity with human HBA (114/141 identical positions), with 27 amino acid substitutions occurring throughout the sequence . These differences are distributed across functional domains that affect oxygen binding, subunit interactions, and stability of the hemoglobin tetramer.

Notable substitutions occur in regions that contribute to the alpha1-beta1 interface and the heme pocket, potentially influencing oxygen affinity and cooperative binding. The specific pattern of substitutions reflects both evolutionary constraints on hemoglobin function and adaptations that may correlate with the physiological requirements of tree shrews.

Table 1: Key amino acid differences between Tupaia glis and Human HBA

Note: This table represents key substitutions based on the characterization of Tupaia glis hemoglobin . The complete set of 27 differences is not fully detailed in the available search results.

What expression systems are commonly employed for recombinant production of Tupaia glis HBA?

For recombinant production of mammalian hemoglobins like Tupaia glis HBA, several expression systems have proven effective, each with distinct advantages:

• E. coli expression system: Most commonly used due to its simplicity, rapid growth, and high protein yields. For hemoglobin expression, specialized E. coli strains with modified metabolic pathways for heme synthesis and co-expression of chaperones can enhance proper folding and heme incorporation.

• Yeast expression systems: Saccharomyces cerevisiae and Pichia pastoris offer eukaryotic post-translational modification capabilities while maintaining relatively high yields. These systems are particularly useful when proper folding requires eukaryotic cellular machinery.

• Mammalian cell lines: Though lower yielding, expression in mammalian cells (typically HEK293 or CHO cells) provides the most native-like post-translational modifications and folding environment for mammalian hemoglobins.

The methodology typically involves:

• Codon optimization of the Tupaia glis HBA sequence for the host organism

• Incorporation of purification tags (His-tag, GST, etc.) that can be cleaved post-purification

• Co-expression with heme synthesis enzymes or supplementation with exogenous heme

• Optimization of induction conditions (temperature, inducer concentration, duration)

For hemoglobin alpha chains specifically, co-expression with beta chains often improves stability and solubility of the recombinant product, mimicking the natural assembly process.

What challenges exist in ensuring proper folding and heme incorporation during recombinant expression of Tupaia glis HBA?

Recombinant expression of Tupaia glis HBA presents several significant challenges related to proper protein folding and heme incorporation:

• Heme availability: Unlike endogenous hemoglobin production, recombinant systems often lack coordinated regulation of heme and globin synthesis. Researchers must address this through:

  • Supplementation of growth media with δ-aminolevulinic acid (ALA), a heme precursor

  • Co-expression of heme synthesis enzymes

  • Exogenous heme addition during or after protein expression

• Maintaining solubility: Isolated alpha subunits tend to aggregate without beta subunit partners. Strategies to overcome this include:

  • Lowering expression temperature (16-20°C)

  • Use of solubility-enhancing fusion partners (SUMO, thioredoxin)

  • Co-expression with chaperone proteins (GroEL/GroES)

• Oxidative damage: The heme iron is susceptible to oxidation, potentially damaging the protein. This can be mitigated by:

  • Addition of reducing agents during purification

  • Expression under low-oxygen conditions

  • Incorporation of antioxidants in purification buffers

• Post-expression modifications: Ensuring the correct N-terminal processing, as native HBA typically has its N-terminal methionine removed. This may require:

  • Co-expression with appropriate proteases

  • In vitro enzymatic treatment post-purification

A systematic approach comparing multiple expression conditions is recommended, with analysis of heme incorporation using absorption spectroscopy (A415/A280 ratio) to quantify holoproteins versus apoproteins.

How can site-directed mutagenesis be applied to investigate functional significance of amino acid differences between Tupaia glis HBA and human HBA?

Site-directed mutagenesis offers a powerful approach to systematically investigate the functional significance of the 27 amino acid differences between Tupaia glis and human HBA. An effective research strategy would involve:

• Prioritization of target residues:

  • Focus on divergent residues in functional domains (heme pocket, subunit interfaces, allosteric sites)

  • Identify residues unique to Tupaia compared to other primates

  • Select positions with significant physicochemical property differences

• Experimental design approaches:

  • "Humanization" mutagenesis: Systematically replace Tupaia-specific residues with human counterparts

  • Reciprocal mutations: Introduce Tupaia-specific residues into human HBA

  • Combinatorial mutations: Address groups of spatially or functionally related substitutions

• Methodological workflow:

  • PCR-based site-directed mutagenesis of expression constructs

  • Verification by DNA sequencing

  • Expression in matched systems for direct comparison

  • Functional characterization (oxygen binding, stability, assembly)

• Analytical readouts:

  • Oxygen equilibrium curves to determine P50 and cooperativity (Hill coefficient)

  • Thermal stability measurements (DSC, CD spectroscopy)

  • Subunit assembly kinetics

  • Autoxidation rates and resistance to denaturation

This approach enables researchers to create "evolutionary intermediates" between Tupaia and human hemoglobin, potentially revealing which substitutions represent adaptive changes versus neutral evolution, and identifying key residues responsible for species-specific functional properties.

What analytical techniques are most effective for assessing oxygen binding properties of recombinant Tupaia glis HBA?

Assessment of oxygen binding properties requires specialized techniques that can accurately measure the complex equilibrium between hemoglobin and oxygen. For recombinant Tupaia glis HBA, several complementary methods are recommended:

• Oxygen equilibrium curve (OEC) determination:

  • Tonometry: The gold standard method uses a Hemox-Analyzer to measure oxygen saturation at varying pO₂

  • Thin-layer optical methods: Allow rapid determination with small sample volumes

  • Automated recording systems: Generate full OECs under controlled conditions (pH, temperature, effectors)

• Functional parameter measurements:

  • P₅₀ (oxygen pressure at 50% saturation): Key indicator of oxygen affinity

  • Hill coefficient (n): Measures cooperativity of oxygen binding

  • Bohr effect: Oxygen affinity change with pH

  • Effects of allosteric regulators (2,3-DPG, chloride, CO₂)

• Kinetic measurements:

  • Stopped-flow spectroscopy: Measures oxygen association/dissociation rates

  • Flash photolysis: For CO and O₂ binding kinetics

  • Temperature-jump methods: Assess conformational changes

• Structural correlation techniques:

  • Raman spectroscopy: Provides information on heme-globin interactions

  • Circular dichroism: Monitors conformational changes upon ligand binding

  • X-ray crystallography/NMR: Determines 3D structural changes in different ligation states

Table 2: Recommended parameters for oxygen binding studies of recombinant Tupaia glis HBA

When working with isolated alpha subunits, researchers should note that some properties will differ from those of intact hemoglobin tetramers, particularly cooperative binding. Comparative studies with human HBA under identical conditions are essential for meaningful interpretation.

How do post-translational modifications differ between native and recombinant Tupaia glis HBA, and what impact might these differences have on protein function?

Post-translational modifications (PTMs) can significantly differ between native and recombinant Tupaia glis HBA depending on the expression system used, potentially affecting structure, function, and stability:

• Common PTM differences:

  • N-terminal processing: Native HBA typically has N-terminal methionine removed and may be N-acetylated; recombinant proteins often retain the initiator methionine or contain affinity tag remnants

  • Oxidative modifications: Recombinant HBA frequently shows higher levels of oxidized residues (Met, Cys, Tyr) due to expression and purification conditions

  • Glycation: Native hemoglobin accumulates non-enzymatic glycation in vivo; recombinant proteins typically lack these modifications

• Expression system-specific differences:

  • E. coli: No glycosylation, often lacks N-terminal processing enzymes

  • Yeast: Hyperglycosylation, different glycan structures than mammalian cells

  • Mammalian cells: Most native-like PTMs but may have cell-specific modifications

• Functional impacts:

  • Altered N-terminus can affect protein stability and susceptibility to proteolysis

  • Oxidative modifications typically reduce oxygen binding affinity and increase methemoglobin formation

  • Glycation alters oxygen affinity and protein half-life

• Analytical approaches to characterize PTMs:

  • Mass spectrometry: LC-MS/MS with peptide mapping for comprehensive PTM profiling

  • Isoelectric focusing: Detects charge variants from modifications

  • Western blotting: Using PTM-specific antibodies

  • RP-HPLC: Separation of differently modified protein species

To minimize these differences, researchers should consider:

• Using mammalian expression systems for most native-like PTMs

• Incorporating N-terminal processing enzymes in prokaryotic expression systems

• Adding antioxidants during expression and purification

• Implementing rigorous quality control to verify PTM status

Table 3: Comparison of PTMs between native and recombinant Tupaia glis HBA

What techniques can be used to study the interaction between recombinant Tupaia glis HBA and HBB subunits?

Understanding the assembly of hemoglobin tetramers from alpha and beta subunits is critical for functional hemoglobin studies. Several techniques are available to study these interactions:

• Biophysical methods:

  • Isothermal Titration Calorimetry (ITC): Provides direct measurement of binding thermodynamics (ΔH, ΔS, KD)

  • Surface Plasmon Resonance (SPR): Offers real-time kinetic data on association and dissociation rates

  • Analytical Ultracentrifugation (AUC): Determines assembly states and binding constants in solution

  • Size Exclusion Chromatography (SEC): Monitors formation of dimers and tetramers

• Structural approaches:

  • X-ray crystallography: Provides atomic-level details of interface contacts

  • Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): Maps interaction surfaces and conformational changes

  • Cryo-EM: Increasingly useful for visualizing assembly intermediates

  • NMR spectroscopy: Provides dynamics information and maps interaction sites

• Functional studies:

  • Oxygen binding cooperativity: The Hill coefficient reflects successful assembly of functional tetramers

  • Allosteric regulation: Response to modulators like 2,3-DPG requires proper quaternary structure

  • Thermal stability measurements: Properly assembled tetramers show characteristic stability profiles

• Molecular engineering approaches:

  • Cross-linking studies: Using bifunctional reagents to trap interaction states

  • FRET-based assays: Using fluorescently labeled subunits to monitor assembly

  • Mutagenesis of interface residues: Systematic modification of contact surfaces

For recombinant Tupaia glis hemoglobin specifically, researchers should consider comparing homologous (Tupaia HBA + Tupaia HBB) versus heterologous (Tupaia HBA + human HBB) assemblies to assess evolutionary constraints on subunit compatibility. This can reveal whether the 27 amino acid differences in the alpha chain affect the alpha-beta interface and subsequent tetramer formation.

How can CRISPR-Cas9 technology be applied to study Tupaia glis HBA gene regulation in vivo?

CRISPR-Cas9 technology offers powerful approaches to study HBA gene regulation in Tupaia glis models, enabling precise genomic modifications:

• Gene regulatory element analysis:

  • Enhancer/promoter editing: Targeted mutations in suspected regulatory regions

  • CRISPR interference (CRISPRi): Using catalytically inactive Cas9 (dCas9) fused to repressor domains to temporarily inhibit transcription

  • CRISPR activation (CRISPRa): Using dCas9 fused to activator domains to enhance transcription

• Chromatin structure and epigenetic regulation:

  • Epigenome editing: Using dCas9 fused to epigenetic modifiers (e.g., DNMT, TET, HAT, HDAC) to alter specific epigenetic marks

  • Chromatin conformation studies: Using CRISPR to insert recognition sites for 3C/4C/Hi-C techniques

• Humanization approaches:

  • Replacing regulatory elements: Substituting Tupaia HBA regulatory regions with human counterparts

  • Knock-in mutations: Introducing specific human variants to study their effects

• Advanced delivery methods for tree shrew models:

  • Lentiviral vectors: Efficient for cell culture and potential for in vivo application

  • Adeno-associated virus (AAV): Good tropism for various tissues including liver (primary site of fetal hemoglobin production)

  • Lipid nanoparticles (LNPs): Emerging technology for Cas9 RNP delivery

For implementation in Tupaia models, several considerations are important:

• Protospacer design: Use Tupaia-specific genome data to design highly specific gRNAs

• Off-target analysis: Comprehensive analysis using Tupaia genome sequences

• Delivery optimization: Develop protocols specific for tree shrew cells or tissues

• Homology-Independent Targeted Integration (HITI): Can improve knock-in efficiency in non-dividing cells

Table 4: CRISPR approaches for studying Tupaia glis HBA regulation

What are the implications of Tupaia glis HBA structural differences for using tree shrews as animal models in hemoglobinopathy research?

The structural differences between Tupaia glis HBA and human HBA have several important implications for using tree shrews as models in hemoglobinopathy research:

• Comparative advantages:

  • Tree shrews (Tupaia spp.) offer a closer evolutionary model to humans than rodents, with approximately 80.9% sequence identity in the HBA protein

  • Their small size, relatively short generation time, and established laboratory protocols make them more practical than primate models

  • Their susceptibility to human pathogens supports their use in studying infectious disease impacts on hemoglobin function

• Structural considerations:

  • The 27 amino acid differences in HBA may affect interpretation of results when studying human hemoglobinopathies

  • Key differences in functional regions may result in altered oxygen binding characteristics

  • Potential differences in post-translational modifications and protein stability must be accounted for

• Specific research applications:

  • Structure-function studies: Tree shrews provide an intermediate evolutionary model between humans and more distant mammals

  • Gene regulation research: The alpha-globin gene cluster organization in tree shrews offers insights into regulatory evolution

  • Genetic modification models: Tree shrews can be engineered with humanized hemoglobin genes using CRISPR-Cas9

• Limitations to consider:

  • Differences in hemoglobin concentration, red cell lifespan, and erythropoietic regulation

  • Variations in oxygen affinity and response to allosteric modulators

  • Potential differences in globin gene switching during development

For optimal use in hemoglobinopathy research, researchers should:

• Thoroughly characterize baseline hemoglobin function in tree shrews

• Consider creating humanized models with knock-in of human HBA/HBB genes

• Establish tree shrew-specific reference ranges for hematological parameters

• Develop tree shrew-specific reagents (antibodies, assays) for hemoglobin analysis

Tree shrews have demonstrated value as experimental models for hepatitis virus infections , suggesting they may similarly serve as useful models for studying hemoglobinopathies once the appropriate baseline characterization is complete.

What purification strategies yield the highest purity and functional integrity for recombinant Tupaia glis HBA?

Purification of recombinant Tupaia glis HBA requires carefully designed strategies to maintain functional integrity while achieving high purity. The following multi-step approach is recommended:

• Initial capture methods:

  • Affinity chromatography: If expressed with affinity tags (His-tag, GST, etc.)

    • IMAC (Immobilized Metal Affinity Chromatography) for His-tagged constructs

    • Glutathione-Sepharose for GST fusion proteins

  • Ion exchange chromatography (IEX): Exploiting HBA's isoelectric point (pI ≈ 8.0-8.3)

    • SP-Sepharose (cation exchange) at pH 6.5-7.0

    • Q-Sepharose (anion exchange) at pH 8.5-9.0

• Intermediate purification:

  • Hydrophobic interaction chromatography (HIC): Using the hydrophobic patches on HBA

  • Size exclusion chromatography (SEC): Separating monomers, dimers, and higher-order aggregates

• Polishing steps:

  • Hydroxyapatite chromatography: Excellent for removing endotoxins and DNA contaminants

  • Endotoxin removal: Critical for samples intended for biological assays

• Heme status optimization:

  • Hemin reconstitution: Ensuring full heme occupancy

  • Removal of excess heme: Typically using hydrophobic chromatography

Table 5: Optimized purification protocol for recombinant Tupaia glis HBA

Critical quality control tests after purification should include:

• Spectroscopic analysis (A415/A280 ratio for heme incorporation)

• SDS-PAGE and mass spectrometry for purity and identity

• Circular dichroism for secondary structure assessment

• Functional testing (oxygen binding)

• Endotoxin testing (LAL assay)

Throughout all purification steps, maintaining reducing conditions (typically 1-5 mM DTT or equivalent) is essential to prevent oxidation of heme iron and reactive amino acid side chains.

What strategies can address the problem of heme loss during purification of recombinant Tupaia glis HBA?

Heme loss is a common challenge during purification of recombinant hemoglobin subunits, including Tupaia glis HBA. Effective strategies to address this problem include:

• Buffer optimization:

  • pH control: Maintain pH between 7.0-8.0 where heme-globin interaction is strongest

  • Ionic strength: Use moderate salt concentrations (100-150 mM NaCl) to minimize electrostatic disruption

  • Stabilizing additives: Include glycerol (10-20%) to enhance hydrophobic interactions

• Redox environment management:

  • Reducing agents: Include 1-5 mM DTT, β-mercaptoethanol, or TCEP to prevent oxidation

  • Oxygen exclusion: Perform purification under nitrogen atmosphere or add glucose oxidase system

  • Metal chelators: Add EDTA (1 mM) to minimize metal-catalyzed oxidation

• Heme supplementation strategies:

  • Co-purification with excess heme: Add 1.2-1.5 molar excess of hemin during lysis

  • Reconstitution steps: Include dedicated step for hemin reincorporation

  • Hemin preparation: Use freshly prepared hemin dissolved in minimal NaOH or DMSO

• Temperature considerations:

  • Reduced temperature: Perform all steps at 4°C to minimize thermal denaturation

  • Avoid freeze-thaw cycles: Store as concentrated solution with stabilizers

• Chromatographic considerations:

  • Column selection: Use materials with minimal interaction with heme groups

  • Flow rates: Use slow flow rates to minimize shear forces

  • Gradient slopes: Use shallow gradients for elution

Table 6: Troubleshooting guide for heme retention in Tupaia glis HBA purification

A spectroscopic monitoring protocol is essential throughout purification:

• A415/A280 ratio should remain >2.5 for fully heme-saturated protein

• Absorption maxima at approximately 415nm (Soret), 540nm and 575nm (Q bands) for ferrous HBA

• Transition to a single peak at 630nm indicates conversion to methemoglobin

Implementing these strategies can increase heme retention from typical values of 40-60% to >90% in final purified recombinant Tupaia glis HBA.